Results 201 to 210 of about 87,588 (241)

The evolution of the multidrug-resistant and globally distributed ST2 Acinetobacter baumannii in China. [PDF]

BMC Microbiol
Zhang G, Zhou Y, Yan B, Wu C, Yang Y, Qiu T, Wu J, Wen S, Chen Y, Deng X, Tian GB, Zhong LL.   +11 more
europepmc   +1 more source

Accelerated stress CMR for the detection of significant coronary artery disease: a prospective randomized diagnostic accuracy study. [PDF]

Eur Heart J Cardiovasc Imaging
Elshibly M, Shergill S, Velvet A, Gohar A, Pattani S, Parke KS, England R, Moafi A, Hudson G, Khoo J, O'Regan DP, Wu O, Adlam D, Kellman P, McIntosh A, McConnachie A, Ladwiniec A, McCann GP, Arnold JR.   +18 more
europepmc   +1 more source

Co-Targeting PD-1 and IL-33/ST2 Pathways for Enhanced Acquired Anti-Tumor Immunity in Breast Cancer. [PDF]

Int J Mol Sci
Jovanović MZ, Jurišević M, Jovanović M, Gajović N, Jocić M, Jovanović MM, Milev B, Vasiljev KD, Jovanović I.   +8 more
europepmc   +1 more source

Transcriptomic and proteomic analysis show minimal role for mast cell ST2 in primary Heligmosomoides polygyrus bakeri infection

Ong NWP, Hodge SH, Baker CP, Smyth DJ, Frangova T, McSorley HJ.   +5 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

The Biology of ST2: The International ST2 Consensus Panel

The American Journal of Cardiology, 2015
ST2 is a member of the interleukin 1 receptor family with 2 main isoforms: transmembrane or cellular (ST2L) and soluble or circulating (sST2) forms. ST2 is the receptor of the IL-33, which is an IL-1-like cytokine that can be secreted by living cells in response to cell damage.
Domingo A, Pascual-Figal, James L, Januzzi   +1 more
openaire   +4 more sources

ST2 in Pulmonary Disease

The American Journal of Cardiology, 2015
In recent years, numerous studies have focused on the use of soluble ST2 (sST2) as a clinical biomarker for cardiovascular disease. However, much preclinical data points to involvement of the ST2 pathway in inflammation, and specifically in pulmonary inflammation. This report summarizes the current body of clinical data suggesting the potential role of
Ednan K, Bajwa, Alexandre, Mebazaa, James L, Januzzi   +2 more
openaire   +2 more sources

Soluble ST2—Analytical Considerations

The American Journal of Cardiology, 2015
Suppression of tumorigenicity 2 (ST2, also known as interleukin [IL]-1 receptor-like-1) is an IL-1 receptor family member with transmembrane (ST2L) and soluble isoforms (sST2). ST2L is a membrane-bound receptor, and IL-33 is the functional ligand for ST2L.
Thomas, Mueller, Allan S, Jaffe
openaire   +2 more sources